Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia

American Journal of Cardiology

Volumn 110, Issue 9, 2012, Pages 1296-1301

  Guo, Jinrui ^a   Meng, Fanbo ^b   Ma, Ning ^c   Li, Chunhua ^a   Ding, Zhenjiang ^a   Wang, Hong ^a   Hou, Ruitian ^a   Qin, Yingjie ^a  

^a CHENGDE MEDICAL COLLEGE   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c Daqing Oil Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; FENOFIBRATE; FLUINDOSTATIN; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; META ANALYSIS; MIXED HYPERLIPIDEMIA; MONOTHERAPY; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT;

AGE FACTORS; AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SAFETY MANAGEMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84867405217     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.06.050     Document Type: Article

References (20)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
2. G.L. Vega, P.T. Ma, N.B. Cater, N. Filipchuk, S. Meguro, A.B. Garcia-Garcia, S.M. Grundy Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome Am J Cardiol 91 2003 956 960
3. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff, W.C. Cushman, D.G. Simons-Morton ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
4. M.H. Davidson, M.W. Rooney, J. Drucker, H. Eugene Griffin, S. Oosman, M. Beckert LCP-AtorFen Investigators Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study Clin Ther 31 2009 2824 2838
5. V.G. Athyros, D.P. Mikhailidis, A.A. Papageorgiou, T.P. Didangelos, A. Peletidou, D. Kleta, A. Karagiannis, A.I. Kakafika, K. Tziomalos, M. Elisaf Targeting vascular risk in patients with metabolic syndrome but without diabetes Metabolism 54 2005 1065 1074
6. S.M. Grundy, G.L. Vega, Z. Yuan, W.P. Battisti, W.E. Brady, J. Palmisano Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am J Cardiol 95 2005 462 468
7. G. Derosa, A.E. Cicero, G. Bertone, M.N. Piccinni, L. Ciccarelli, D.E. Roggeri Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial Clin Ther 26 2004 1599 1607
8. M. Farnier, J. Ducobu, L. Bryniarski Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy Am J Cardiol 106 2010 787 792
9. M. Farnier, E. Roth, B. Gil-Extremera, G.F. Mendez, G. Macdonell, C. Hamlin, I. Perevozskaya, M.J. Davies, D. Kush, Y.B. Mitchel Ezetimibe/ Simvastatin + Fenofibrate Study Group Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia Am Heart J 153 suppl 2007 e1 e8
10. J.C. Fruchart, F. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, R. Ceska, M.J. Chapman, P.M. Dodson, P. Fioretto, H.N. Ginsberg, T. Kadowaki, J.M. Lablanche, N. Marx, J. Plutzky, Z. Reiner, R.S. Rosenson, B. Staels, J.K. Stock, R. Sy, C. Wanner, A. Zambon, P. Zimmet The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 suppl 2008 1K 34K
11. J. Shepherd, P. Barter, R. Carmena, P. Deedwania, J.C. Fruchart, S. Haffner, J. Hsia, A. Breazna, J. LaRosa, S. Grundy, D. Waters Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 29 2006 1220 1226
12. A. Tenenbaum, E.Z. Fisman "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD lipid study Cardiovasc Diabetol 9 2010 24
13. M.H. Davidson Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions Expert Opin Drug Saf 5 2006 145 156
14. P.H. Jones, M.H. Davidson Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin Am J Cardiol 95 2005 120 122
15. J. Chen, P. Muntner, L.L. Hamm, D.W. Jones, V. Batuman, V. Fonseca, P.K. Whelton, J. He The metabolic syndrome and chronic kidney disease in U.S. adults Ann Intern Med 140 2004 167 174
16. I.H. Chang, J.H. Han, S.C. Myung, K.W. Kwak, T.H. Kim, S.W. Park, N.Y. Choi, W.H. Chung, S.H. Ahn Association between metabolic syndrome and chronic kidney disease in the Korean population Nephrology (Carlton) 14 2009 321 326
17. G. Kidney Disease Outcomes Quality Initiative K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease Am J Kidney Dis 41 suppl 2003 S1 S91
18. M.E. Molitch Management of dyslipidemias in patients with diabetes and chronic kidney disease Clin J Am Soc Nephrol 1 2006 1090 1099
19. V. Launay-Vacher, H. Izzedine, G. Deray Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients Int J Cardiol 101 2005 9 17
20. A.J. Bergman, G. Murphy, J. Burke, J.J. Zhao, R. Valesky, L. Liu, K.C. Lasseter, W. He, T. Prueksaritanont, Y. Qiu, A. Hartford, J.M. Vega, J.F. Paolini Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans J Clin Pharmacol 44 2004 1054 1062